Neuromuscular Blocking Drugs Market Outlook:
Neuromuscular Blocking Drugs Market size was valued at USD 4.3 billion in 2025 and is projected to reach USD 7.5 billion by the end of 2035, rising at a CAGR of 5.8% during the forecast period, i.e., 2026-2035. In 2026, the industry size of neuromuscular blocking drugs is assessed USD 4.5 billion.
The global neuromuscular blocking drugs market is driven by the critical care requirements and the rising patient pool. As per the NLM article in May 2024, nearly 234.2 million surgical procedures were performed globally, involving neuromuscular blocking drugs for intubation or muscular relaxation. Further, the market is driven by the rise in the aging population and prevalence of chronic disease. In parts of Latin America and the Asia Pacific, the public health systems have maximized access to anesthesia-aided procedures. As per the WHO report, the developing countries are broadening their healthcare capacities. This expansion in the patient pool necessitates support for long-term stability and volume growth for the neuromuscular blocking drugs (NMBD) market.
On the supply chain side, the production of neuromuscular blocking drugs is highly dependent on Active Pharmaceutical Ingredients (API). The API are mainly manufactured in China, India, and parts of Europe, with final formulation made in the U.S. The Muscular Dystrophy Association report in June 2024 states that NIH has allocated USD 47.08 billion for therapies and drugs related to neuromuscular research. Delay in the raw materials from China has led to the rise in the value chain during the period 2021 to 2022. Further, government-led investment in anesthesia safety mechanisms and research has also risen.
